Chronic Myelomonocytic Leukemia

Watchlist

(log in to enable)

Retrieved

2021-01-23

Source

Orphanet

Trials

—

Genes

KDM6A, TET2, ETV6, DNMT3A, PDGFRB, EZH2, SRSF2, ASXL1, KIT, JAK2, BCR, SETBP1, RUNX1, CD34, KRAS, ABL1, CBL, CSF2, KMT2A, FLT3, NRAS, HIP1, FANCB, SF3B1, PARP1, IL3RA, U2AF1, HRAS, GFM1, RET

KDM6A, TET2, ETV6, DNMT3A, PDGFRB, EZH2, SRSF2, ASXL1, KIT, JAK2, BCR, SETBP1, RUNX1, CD34, KRAS, ABL1, CBL, CSF2, KMT2A, FLT3, NRAS, HIP1, FANCB, SF3B1, PARP1, IL3RA, U2AF1, HRAS, GFM1, RET, FGFR1OP, MEFV, GATA2, MYC, BAP1, FCGR3B, FCGR3A, TNF, IL10, NPM1, MAP2K7, NUP98, RABEP1, IL3, CNTNAP1, FIP1L1, CSF3R, TP53, LINC01152, MOGS, TMED7-TICAM2, TICAM2, YWHAE, YY1, VEGFA, U2AF1L5, RGPD2, THY1, THPO, PPP1R11, SOAT1, H3P23, SCT, ROS1, ELL, ZNRD2, SMC1A, NRP2, TET3, MLKL, MIR142, CBLL2, PDCD1LG2, MIR150, MUL1, XYLT2, PCBP4, PAG1, ETNK1, MIR223, MIR424, BCL11A, TRIM33, DDX41, TMED7, CD274, DLL1, RARS1, KDM6B, KAT7, DCTN6, PRR14L, IL32, OPN1LW, NF1, PTPRC, CREBBP, FRA16B, FLT3LG, FGFR1, F3, MECOM, ERCC1, EPO, EPHB2, EIF4E, EGR2, CYBB, CTLA4, CSF1, COL11A2, GP1BA, CCR7, CDKN2A, CDKN1A, CD68, CD14, CD6, BRAF, BLVRB, BCHE, ARG1, BIRC5, APEX1, ANPEP, FUT4, GRB2, PTPN11, MTTP, PSMD9, PSMB6, MAPK1, PDGFRA, PDE4A, PRKN, PAFAH1B1, PEBP1, ACHE, NELL2, NBN, MYH10, MYB, KITLG, CXCL1, LYZ, JUN, ITGAM, IL18, IL4, IL1B, IGF2, IFI27, ID1, HTR1B, AGFG2, HOXA9, HTT, H3P10

Drugs

Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus, Imatinib mesilate ( GLEEVEC, GLIVEC, IMATINIB TEVA, IMATINIB TEVA B.V. ), haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate

Interested in hearing about new therapies?

A rare myelodysplastic/myeloproliferative neoplasm characterized by a spectrum of clinical, hematological, and morphological features, ranging from predominantly myelodysplastic to mainly myeloproliferative in nature. Infiltration of the liver, spleen, lymph nodes, and other organs is common. Persistent peripheral blood monocytosis with monocytes accounting for more than 10% of leukocytes is the hallmark of the condition. Blasts constitute less than 20% of the cells in the peripheral blood and bone marrow. Other abnormalities are variable. Patients may present with constitutional symptoms, signs and symptoms of hematopoietic insufficiency, and hepatosplenomegaly. The disease is associated with a risk of transformation to acute myeloid leukemia.